Type I insulin-like growth factor receptor function in breast cancer

Breast Cancer Research and Treatment

Volumn 47, Issue 3, 1998, Pages 255-267

  Surmacz, Ewa ^a   Guvakova, Marina A ^a   Nolan, Mary K ^a   Nicosia, Roberto F ^a,b   Sciacca, Laura ^a,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Adhesion; Apoptosis; Breast cancer; IGF I receptor; IRS 1; SHC

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; INTERLEUKIN 1; PROGESTERONE; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; UVOMORULIN;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BREAST; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CANCER RECURRENCE; CELL ADHESION; CELL AGGREGATION; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; FEMALE; HUMAN; METASTASIS; MONOLAYER CULTURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; HUMANS; RECEPTOR, IGF TYPE 1; TUMOR CELLS, CULTURED;

EID: 0031985633     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005907101686     Document Type: Article

References (64)

1. Rubin R, Baserga R: Biology of disease. IGF-IR. Its role in cell proliferation, apoptosis and tumorigenicity. Lab Invest 73:311-331, 1995
2. Dickson RB, Lippman ME: Growth factors in breast cancer. Endocr Rev 16:559-589, 1995
3. Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 49:415-421, 1995
4. Peyrat JP, Bonneterre J: Type I IGF receptor in human breast disease. Breast Cancer Res Treat 22: 59-67, 1992
5. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736-3740, 1993
6. Pezzino V, Papa V, Milazzo G, Gliozzzo B, Russo P, Scalia PL: Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann NY Acad Sci 784: 189-201, 1996
7. Kleinman D, Karas M, Roberts CT Jr, LeRoith D, Philip M, Segev Y, Levy J, Sharoni Y: Modulation of insulin-like growth factor I receptors and membrane-associated IGF binding proteins in endometrial cancer cells by estradiol. Endocrinology 136:2531-2537, 1995
8. Collecchi P, Giannessi PG, Baldini E, Naccarato AG, Passoni A, Bevilaqua G, Conte PF: Effects of primary chemotherapy on biological parameters of locally advanced breast cancer. Ann NY Acad Sci 784:419-426, 1996
9. Railo MJ, Smitten K, Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A:307-311, 1994
10. Bonneterre J, Peyrat JP, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res 50: 6931-6935, 1990
11. Foekens JA, Portengen H, Janssen M, Klijn JGM: Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63:2139-2147, 1989
12. Pekonen F, Partanen S, Makinen T, Rutanen E-M: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 48:1343-1347, 1988
13. Foekens J, Portengen H, van Putten WLJ, Trapman AM, Reubi J-C, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor I, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989
14. Berns EM, Klijn JGM, van Staveren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast cancer. Cancer Res 52:1036-1039, 1992
15. Webster NJG, Resnic JL, Reichart DB, Strauss B, Haas M, Seely BL: Repression of the insulin receptor promoter by the tumor suppressor gene product p53 -a possible mechanism for receptor overexpression in breast cancer. Cancer Res 56:2781-2788, 1996
16. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Rachamandran J, Fujita-Yamaguchi Y: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5:2503-2512, 1986
17. Soos MA, Nave BT, Siddle K: Immunological studies of type I IGF receptors and insulin receptors: characterization of hybrid and atypical receptor subtypes. Adv Exp Med Biol 343:145-157, 1993
18. Myers M, Sun XJ, White M: The IRS-1 signaling system. TIBS 19:289-293, 1994
19. He W, Craparo A, Zhu Y, O'Neill TJ, Wang LM, Pierce JH, Gustafson TA: Interaction of insulin receptor substrate 2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J Biol Chem 271:11641-11645, 1996
20. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavaool F, Forni G, Nicoletti I, Grignani F, Pawson T, Pelicci PG: A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70:93-104, 1992
21. Giorgetti S, Pelicci PG, Pelicci G, van Obberghen E: Involvement of Src-homology/collagen (SHC) proteins in signaling through the insulin receptor and the insulin-like growth factor I receptor. Eur J Biochem 223:195-202, 1994
22. Lamothe B, Bucchini D, Jami J, Joshi RL: Interaction of p85 subunit of PI-3 kinase with insulin and IGF-I receptors analyzed using the two-hybrid system. FEBS Letters 371:51-55, 1995
23. Morrione A, Valentinis B, Li S, Ooi JYT, Margolis B, Baserga R: Grb10: A new substrate of the insulin-like growth factor I receptor. Cancer Res 56:3165-3167, 1996
24. O'Neill TJ, Rose DW, Pillay TS, Hotta K, Olefsky JM, Gustafson TA: Interaction of a GRB-IR splice variant (a human GRB10 homolog) with the insulin and insulin-like growth factor I receptor. Evidence for a role in mitogenic signaling. J Biol Chem 271:22506-22513, 1996
25. Beitner-Johnson D, Blakesley VA, Shen-Orr Z, Jimenez M, Stannard B, Wang LM, Pierce J, LeRoith D: The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-1 (IGF-1) and enhanced IGF-1 signaling. J Biol Chem 271:9287-9290, 1996
26. Argetsinger LS, Hsu GW, Myers MG, Billestrup N, White MF, Carter-Su C: Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of IRS-1. J Biol Chem 270: 14685-14692, 1995
27. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Borrello MG, Gegatto O, Di Fiore PP, Pelicci PG: Constitutive phosphorylation of SHC proteins in human tumors. Oncogene 11:899-907, 1995
28. Habib T, Herrera R, Decker SJ: Activators of protein kinase C stimulate association of SHC and the PEST tyrosine phosphatase. J Biol Chem 269:25243-25246, 1994
29. Guvakova M, Surmacz E: Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 231:149-162, 1997
30. Doerr M, Jones J: The roles of integrins and extracellular matrix proteins in the IGF-I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 271:2443-2447, 1996
31. Vuori K, Ruoslahti E: Association of insulin receptor substrate-1 with integrins. Science 266:1576-1578, 1994
32. Giancotti F: Signal transduction by the α6/β4 integrin: charting the path between laminin binding and nuclear events. J Cell Science 109:1165-1172
33. Quinn KA, Treston AM, Unsworth FJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F: Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271:11477-11483, 1996
34. Surmacz E, Burgaud J-L: Overexpression of IRS-1 in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clin Cancer Res 1:1429-1436, 1995
35. Ellis MJC, Singer C, Hornby A, Rasmussen A, Cullen KJ: Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer. Breast Cancer Res Treat 31:249-261, 1994
36. Arteaga C: Interference of the IGF-I system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 22:101-106, 1992
37. Brunner N, Spang-Thomsen M, Cullen K: The T 61 human breast cancer xenograft: An experimental model of estrogen therapy of breast cancer. Breast Cancer Res Treat 39:87-92, 1996
38. Ravera F, Miglietta L, Pirani P, Ferrini S, Favoni RE: Suramin-induced growth inhibition and insulin-like growth factor-I binding blockade in human breast carcinoma cell lines: potentially related events. Eur J Cancer 29A:225-230, 1993
39. Figueroa JA, Yee D: Insulin-like growth factor binding proteins: potential inhibitors of cancer cell growth. Drugs of the Future 19:477, 1994
40. Neuenschwander S, Roberts CT Jr, LeRoith D: Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136:4298-4303, 1995
41. Manni A, Wright C, Buck H: Growth factor involvement in the multihormonal regulation of MCF-7 breast cancer cell growth in soft agar. Breast Cancer Res Treat 20:43-52, 1991
42. Nolan M, Jankowska L, Prisco M, Xu S, Guvakova M, Surmacz E: Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int J Cancer, in press
43. Surmacz E, Sell C, Swantek J, Kato H, Roberts CT, LeRoith D, Baserga R: Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor. Exp Cell Res 218:370-380, 1995
44. Bracke ME, Vyncke BM, Bruyneel EA, Vermeulen SJ, De Bruyne GK, Van Larebeke NA, Vleminck K, Van Roy FM, Mareel MM: Insulin-like growth factor I activates the invasion suppressor function of E-cadherin in MCF-7 human mammary carcinoma cells in vitro. Br J Cancer 68:282-289, 1993
45. Rocha RL, Hilsenbeck SG, Jackson JG, Van Der Berg CL, Weng C-W, Lee AV, Yee D: Insulin-like growth factor binding protein-3 and insulin receptor substrate 1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res 3:103-109, 1997
46. Stein D, Wu J, Fuqua SAW, Roonprapunt C, Yajnik V, D'Eustachio P, Moskow JJ, Buchberg AM, Osborne CK, Margolis B: The SH2 domain protein GRB-7 is co-amplified, overexpressed, and in a tight complex with HER2 in breast cancer. EMBO J 13:1331-1340, 1994
47. Daly RJ, Binder MD, Sutherland RL: Overexpression of GRB2 gene in human breast cancer cell lines. Oncogene 9:2723-2727, 1994
48. Edelmann LA, Santos-Moore A, Clark JW, Frackelton AR Jr: Modulation of SHC tyrosine phosphorylation in breast cancer cell lines. Proc Am Assoc Cancer Res 35:A2666, 1994
49. Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoith D, Levy J, Sharoni Y: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 137:1089-1095, 1996
50. Van der Burg B, Rutteman GR, Blankenstein MA, de Latt SW, Zoelen EJJ: Mitogenic stimulation of human breast cancer cells in growth factor-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 134:101-108, 1988
51. Stewart A, Johnson MD, May FEB, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172-21178, 1990
52. Jordan CV: Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 31:41-52, 1994
53. Freiss G, Rochefort H, Vignon F: Mechanism of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Biochem Biophys Res Commun 173:919-926, 1990
54. Kawamura I, Lacey E, Mizota T, Tsujimoto S, Nishigaki F, Manda T, Shimomura K: The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. Anticancer Res 14: 427-432, 1994
55. De Cupis A, Noonan D, Pirani P, Ferrera A, Clerico L, Favoni RE: Comparison between novel steroid-like and conventional nonsteroidal antiestrogens in inhibiting oestradiol-and IGF-I-induced proliferation of human breast cancer-derived cells. Br J Pharm 116: 2391-2400, 1995
56. Freiss G, Vignon F: Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Mol Endocrinol 8:1389-1396, 1994
57. McCotter D, van den Berg HW, Boylan M, McKibben B: Changes in insulin-like growth factor 1 receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. Cancer Letters 99:239-245, 1996
58. Migliaccio A, Di Domenico M, Castoria G, deFalco A, Bontempo P, Nola E, Auricchio F: Tyrosine kinase/ p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15:1292-1300, 1996
59. Katzenellenbogen BS, Norman MJ: Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor I, serum, and estrogen. Endocrinology 126:891-898, 1990
60. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995
61. Goldfine ID, Papa V, Vigneri R, Siiteri P, Rosenthal S: Progetsin regulation of insulin and insulin-like growth factor I receptors in cultured human breast cancer cells. Breast Cancer Res Treat 22:69-79, 1992
62. Werner H, Karnieli E, Rauscher FJ, LeRoith D: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93:8318-8323, 1996
63. Costantino A, Vinci C, Mineo R, Frasca F, Pandini G, Milazzo G, Vigneri R, Belfiore A: Interleukin-1 blocks insulin and insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity. Endocrinology 137:4100-4107, 1996
64. Guvakova M, Surmacz E: Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 57:2606-2610, 1997